Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Enters Japan Through Divested Novartis Portfolio

This article was originally published in Scrip

Executive Summary

Sun Pharmaceutical Industries Ltd. is entering the Japanese pharma market by acquiring a bundle of 14 established prescription brands from Novartis AG's local subsidiary, in an anticipated move that echoes a similar transaction between Takeda Pharmaceutical Co. Ltd. and Teva Pharmaceutical Industries Ltd. last year.

You may also be interested in...



Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance

Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.

Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance

Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.

Astellas Offloads Japan Product Basket To Private Equity Group

Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel